Erythromycin
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 3 |
Source: | FDA Structured Product Label |
---|
Side effects: | 4 |
Source: | FDA Structured Product Label |
---|
Side effects: | 6 |
Source: | FDA Structured Product Label |
---|
Side effects: | 7 |
Source: | FDA Structured Product Label |
---|
Side effects: | 8 |
Source: | Medsafe |
---|
Side effects: | 13 |
Source: | FDA Structured Product Label |
---|
Side effects: | 18 |
Source: | FDA |
---|
Side effects: | 21 |
Source: | FDA Structured Product Label |
---|
Side effects: | 22 |
Source: | Health Canada |
---|
Side effects: | 22 |
Source: | FDA Structured Product Label |
---|
Side effects: | 22 |
Source: | FDA Structured Product Label |
---|
Side effects: | 22 |
Source: | FDA Structured Product Label |
---|
Side effects: | 22 |
Source: | FDA Structured Product Label |
---|
Side effects: | 22 |
Source: | FDA |
---|
Side effects: | 23 |
Source: | FDA Structured Product Label |
---|
Side effects: | 23 |
Source: | FDA Structured Product Label |
---|
Side effects: | 23 |
Source: | FDA Structured Product Label |
---|
Side effects: | 23 |
Source: | FDA Structured Product Label |
---|
Side effects: | 29 |
Source: | medicines.org.au |
---|
Side effects: | 30 |
Source: | Health Canada |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|